BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 34769447)

  • 1. Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies.
    Cilibrasi C; Papanastasopoulos P; Samuels M; Giamas G
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
    Shi T; Song X; Wang Y; Liu F; Wei J
    Front Immunol; 2020; 11():683. PubMed ID: 32411132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The viral approach to breast cancer immunotherapy.
    Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J
    J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?
    Cejalvo JM; Falato C; Villanueva L; Tolosa P; González X; Pascal M; Canes J; Gavilá J; Manso L; Pascual T; Prat A; Salvador F
    Cancer Treat Rev; 2022 May; 106():102392. PubMed ID: 35436729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer.
    Noguchi E; Shien T; Iwata H
    Jpn J Clin Oncol; 2021 Mar; 51(3):321-332. PubMed ID: 33324990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.
    Leko V; Rosenberg SA
    Cancer Cell; 2020 Oct; 38(4):454-472. PubMed ID: 32822573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
    Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
    Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and perspectives for immunotherapy in oesophageal cancer: A look to the future (Review).
    Lampis A; Ratti M; Ghidini M; Mirchev MB; Okuducu AF; Valeri N; Hahne JC
    Int J Mol Med; 2021 Jun; 47(6):. PubMed ID: 33846775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination strategies to maximize the benefits of cancer immunotherapy.
    Zhu S; Zhang T; Zheng L; Liu H; Song W; Liu D; Li Z; Pan CX
    J Hematol Oncol; 2021 Sep; 14(1):156. PubMed ID: 34579759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Brain Tumors.
    Hoang-Minh LB; Mitchell DA
    Curr Treat Options Oncol; 2018 Oct; 19(11):60. PubMed ID: 30311004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer.
    Wu J; Cai J
    Dig Dis Sci; 2021 Feb; 66(2):359-368. PubMed ID: 32140943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic Viruses as an Adjunct to Immune Checkpoint Inhibition.
    Ripp J; Hentzen S; Saeed A
    Front Biosci (Landmark Ed); 2022 May; 27(5):151. PubMed ID: 35638418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.
    Meng Q; He J; Zhong L; Zhao Y
    Int J Med Sci; 2021; 18(11):2294-2302. PubMed ID: 33967605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viroimmunotherapy for breast cancer: promises, problems and future directions.
    Chaurasiya S; Fong Y
    Cancer Gene Ther; 2021 Aug; 28(7-8):757-768. PubMed ID: 33268826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapeutic strategies in breast cancer: A clinical update.
    Zhang JQ; Plitas G
    J Surg Oncol; 2021 Mar; 123(3):710-717. PubMed ID: 33155281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single peptides and combination modalities for triple negative breast cancer.
    Razazan A; Behravan J
    J Cell Physiol; 2020 May; 235(5):4089-4108. PubMed ID: 31642059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and future perspectives of immunotherapy in bladder cancer treatment.
    Wu Z; Liu J; Dai R; Wu S
    Sci China Life Sci; 2021 Apr; 64(4):512-533. PubMed ID: 32926318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodal approaches to improve immunotherapy in breast cancer.
    Basu A; Kodumudi K
    Immunotherapy; 2020 Feb; 12(3):161-165. PubMed ID: 32157934
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.